Bridging the efficacy–effectiveness gap: a regulator's perspective on addressing variability of drug response
about
RELATIVE EFFECTIVENESS IN BREAST CANCER TREATMENT: A HEALTH PRODUCTION APPROACHReal world evidence: An Indian perspectiveNumber of patients studied prior to approval of new medicines: a database analysisWhere Failure Is Not an Option -Personalized Medicine in Astronauts"Threshold-crossing": A Useful Way to Establish the Counterfactual in Clinical Trials?Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data.GetReal in mathematical modelling: a review of studies predicting drug effectiveness in the real world.An analytic framework for aligning observational and randomized trial data: Application to postmenopausal hormone therapy and coronary heart disease.Older adults' satisfaction with a medication dispensing device in home care.The innovative medicines initiative: a European response to the innovation challenge.Patient-centered medicine and patient-oriented research: improving health outcomes for individual patientsExtraction of electronic health record data in a hospital setting: comparison of automatic and semi-automatic methods using anti-TNF therapy as model.Personalizing health care: feasibility and future implications.Observational and clinical trial findings on the comparative effectiveness of diabetes drugs showed agreement.Research designs for proof-of-concept chronic pain clinical trials: IMMPACT recommendationsImpact of a community pharmacist-led medication review on medicines use in patients on polypharmacy--a prospective randomised controlled trial.Bioinformatics and variability in drug response: a protein structural perspective.An Ethical Justification for Expanding the Notion of Effectiveness in Vaccine Post-Market Monitoring: Insights from the HPV Vaccine in CanadaTime trends in statin utilisation and coronary mortality in Western European countries.UNDERSTANDING VARIATIONS IN RELATIVE EFFECTIVENESS: A HEALTH PRODUCTION APPROACHDabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs.Promises and challenges of pharmacogenetics: an overview of study design, methodological and statistical issuesA fresh perspective on comparing the FDA and the CHMP/EMA: approval of antineoplastic tyrosine kinase inhibitors.Payers' Views of the Changes Arising through the Possible Adoption of Adaptive PathwaysEfficacy and effectiveness trials have different goals, use different tools, and generate different messages.PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms.A systematic literature review on the efficacy-effectiveness gap: comparison of randomized controlled trials and observational studies of glucose-lowering drugs.Real-World Experiences With a Direct-Acting Antiviral Agent for Patients With Hepatitis C Virus Infection.Adaptive licensing: taking the next step in the evolution of drug approval.The Nordic prescription databases as a resource for pharmacoepidemiological research--a literature review.Harmonization of reimbursement and regulatory approval processes: a systematic review of international experiences.The risks of risk aversion in drug regulation.Trends and issues in oncology costs.Implications of pharmacogenetics for the therapeutic use of antiepileptic drugs.An analytical framework for assessing drug and therapeutics committee structure and work processes in tertiary Brazilian hospitals.The patient perspective of diabetes care: a systematic review of stated preference research.Regulators should better leverage effectiveness standards to enhance drug value.Early market access of cancer drugs in the EU.Dynamic value assessments in oncology supported by the PACE Continuous Innovation Indicators.Factors Contributing to the Efficacy-Effectiveness Gap in the Case of Orphan Drugs for Metabolic Diseases.
P2860
Q28073800-CD68E676-605C-47BA-BA16-45251157E483Q28074506-008164E5-4909-49FF-B3C4-27B22ECE1B8AQ28488191-9547BF7E-8BF7-4502-A093-9154540BCA79Q28550427-80024A82-778E-4E69-B3B6-ACE822715AABQ28595570-A43BEDE8-7DBD-434E-8682-F269CB9D6AF2Q30234512-AE3689F7-8C15-40DD-B90D-9D2A84F3EB14Q30248472-22755F8A-2CEE-493F-A9D0-C6F73EB5F303Q30696956-229E9C65-43CE-409E-8166-3BC98B70F3CDQ34004889-49008D51-AEC1-4530-BA58-9B8111EBBCA1Q34253090-9A12538D-5FA2-47B4-918C-E62A9904EAB6Q34538048-2818EB94-B9AF-423A-A0FE-FFFA863FE711Q34572340-A5B922E2-3EB3-4D7D-92DC-F485FEC097B4Q34938911-0BEEC94D-269C-4608-AEE5-C76147FCAB10Q35146648-9A6EDAFC-8552-4DF4-B587-D78B85070303Q35846608-D928D614-1AF7-44A9-9A4B-54A6DA03A153Q35997702-0A7277EE-EE9D-4F55-9695-D7BC55C6A56CQ36009999-3760A864-8A5D-4045-9F3A-0B8873303C4FQ36652379-C7D4B8CA-F3EF-4BC5-BD98-D08BD4BAC056Q36773079-E421A1E7-D1D6-40BE-943A-FB744283F342Q36778700-9764EFB3-C9B1-4F4A-9A70-E5884E021AF7Q36841028-18E55FFF-AC28-4861-9B55-102BCD846779Q37082500-A2FF1D27-1505-466A-A3C4-228C4C308075Q37161896-0B691B2B-97B1-4808-89FD-E693434B83AFQ37290101-9F338B3E-F4D2-4B4C-AC87-9B10ABC75EB6Q37300935-D9A67BE8-2486-4EB2-90D4-435D21C8AF59Q37481946-959A8971-9DBC-454C-8293-7D9159184145Q37610459-FFD7F6CE-3EF1-4DAE-A30A-FE66544E128CQ37735832-918CF720-796B-45D9-BD1A-0238F324DA33Q37984169-6C06A2EB-5AD3-46C2-8ADE-7D659AEAC18AQ38109104-7B1D609D-5BFB-4FFF-AF22-C59688F76D35Q38131545-ADACCD4E-2CB6-453B-ADDB-CE0AB8E43ED7Q38162718-875EB945-2020-42D1-AB9A-856CEEE2680CQ38170426-11FB9D15-B297-48DF-A61A-A836A3601D9DQ38181565-CE4D5702-C50A-40A6-896C-D3D3F68016C9Q38188070-8EEEDD6F-5B45-48DC-B8D8-F0C3358DEB61Q38201315-617624FD-0536-4245-9775-9F4CC73C9434Q38231693-D7076804-BACA-4284-BBCA-687E1B76B5C6Q38612833-B1BFFFDC-B57B-4A6A-9D18-5EA8192DEE8BQ38651603-30B532A9-A50F-4479-B175-F04792FED568Q38656087-FDE0302A-0C4C-49DF-B328-2DA75AC0C952
P2860
Bridging the efficacy–effectiveness gap: a regulator's perspective on addressing variability of drug response
description
article
@en
im Juli 2011 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в липні 2011
@uk
name
Bridging the efficacy–effectiv ...... g variability of drug response
@en
Bridging the efficacy–effectiv ...... g variability of drug response
@nl
type
label
Bridging the efficacy–effectiv ...... g variability of drug response
@en
Bridging the efficacy–effectiv ...... g variability of drug response
@nl
prefLabel
Bridging the efficacy–effectiv ...... g variability of drug response
@en
Bridging the efficacy–effectiv ...... g variability of drug response
@nl
P2093
P2860
P356
P1476
Bridging the efficacy–effectiv ...... g variability of drug response
@en
P2093
Alasdair Breckenridge
Brigitte Bloechl-Daum
Bruno Flamion
Christian K. Schneider
Eric Abadie
Hans-Georg Eichler
Hubert Leufkens
Malcolm Rowland
P2860
P2888
P304
P356
10.1038/NRD3501
P577
2011-07-01T00:00:00Z
P6179
1021546762